Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine

키워드

참고문헌 (93)

1. Ferlay J, "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
2. 이경숙, "Gastric Cancer Screening in Korea: Report on the National Cancer Screening Program in 2008", Cancer Research and Treatment, 43(2), pp.83~88 (2011), 대한암학회
3. Hamashima C, "The Japanese guidelines for gastric cancer screening", Jpn J Clin Oncol, 38, pp.259~267 (2008)
4. 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
5. 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2015", Cancer Research and Treatment, 47(2), pp.142~148 (2015), 대한암학회[DOI]
6. Noh SH, "Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial", Lancet Oncol, 15, pp.1389~1396 (2014)
7. Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
8. Nakajima T, "Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group", Lancet, 354, pp.273~277 (1999)
9. Macdonald JS, "Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study", Ann Surg Oncol, 2, pp.488~494 (1995)
10. Engstrom PF, "Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275)", Cancer, 55, pp.1868~1873 (1985)
11. Krook JE, "A prospective, randomized evaluation of intensivecourse 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer", Cancer, 67, pp.2454~2458 (1991)
12. Cunningham D, "East meets west in the treatment of gastric cancer", N Engl J Med, 357, pp.1863~1865 (2007)
13. Japanese Gastric Cancer Association, "Japanese Classification of Gastric Carcinoma - 2nd English Edition -", Gastric Cancer, 1, pp.10~24 (1998)
14. "Cancer JRSfG: Japenese classification of gastric carcinoma" (1995), Kanehara
15. Japanese Gastric Cancer Association, "Japanese gastric cancer treatment guidelines 2010", Gastric Cancer, 14, pp.113~123 (2011)
16. Wu CW, "Nodal dissection for patients with gastric cancer: a randomised controlled trial", Lancet Oncol, 7, pp.309~315 (2006)
17. Sano T, "Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501", J Clin Oncol, 22, pp.2767~2773 (2004)
18. Sasako M, "D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer", N Engl J Med, 359, pp.453~462 (2008)
19. 형우진, "Changes in Treatment Outcomes of Gastric Cancer Surgery Over 45 Years at A Single Institution", Yonsei Medical Journal, 49(3), pp.409~415 (2008), 연세대학교의과대학
20. Bonenkamp JJ, "Extended lymph-node dissection for gastric cancer", N Engl J Med, 340, pp.908~914 (1999)
21. Cuschieri A, "Patient survival after D1 and D2 resections for gastric cancer:long-term results of the MRC randomized surgical trial. Surgical Co-operative Group", Br J Cancer, 79, pp.1522~1530 (1999)
22. Cuschieri A, "Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group", Lancet, 347, pp.995~999 (1996)
23. Bonenkamp JJ, "Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients", Lancet, 345, pp.745~748 (1995)
24. Kim KM, "Major early complications following open, laparoscopic and robotic gastrectomy", Br J Surg, 99, pp.1681~1687 (2012)
25. Songun I, "Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial", Lancet Oncol, 11, pp.439~449 (2010)
26. Martin RC 2nd, "Extended local resection for advanced gastric cancer: increased survival versus increased morbidity", Ann Surg, 236, pp.159~165 (2002)
27. Mansfield PF, "Lymphadenectomy for gastric cancer", J Clin Oncol, 22, pp.2759~2761 (2004)
28. Waddell T, "Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 24(Suppl 6), pp.vi57~vi63 (2013)
29. Ajani JA, "Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines", J Natl Compr Canc Netw, 11, pp.531~546 (2013)
30. Ohashi I, "Pancreatosplenectomy for advanced gastric carcinoma with special reference to lymph nodes metastasis", Jpn J Gastroenterol Surg, 12, pp.993~999 (1979)
31. Maruyama K, "Pancreas-preserving total gastrectomy for proximal gastric cancer", World J Surg, 19, pp.532~536 (1995)
32. Choi YY, "Current practice of gastric cancer treatment", Chin Med J (Engl), 127, pp.547~553 (2014)
33. Oh SJ, "The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer", J Surg Oncol, 99, pp.275~280 (2009)
34. Lee KY, "Impact of splenectomy for lymph node dissection on long-term surgical outcome in gastric cancer", Ann Surg Oncol, 8, pp.402~406 (2001)
35. Bartlett EK, "Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database", Surgery, 156, pp.298~304 (2014)
36. Yu W, "Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer", Br J Surg, 93, pp.559~563 (2006)
37. Kosuga T, "Survival benefits from splenic hilar lymph node dissection by splenectomy in gastric cancer patients: relative comparison of the benefits in subgroups of patients", Gastric Cancer, 14, pp.172~177 (2011)
38. Mönig SP, "Splenectomy in proximal gastric cancer: frequency of lymph node metastasis to the splenic hilus", J Surg Oncol, 76, pp.89~92 (2001)
39. Sasada S, "Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer", Anticancer Res, 29, pp.3347~3351 (2009)
40. Sano T, "Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma:Japan clinical oncology group study JCOG 0110-MF", Jpn J Clin Oncol, 32, pp.363~364 (2002)
41. Kitano S, "Laparoscopy-assisted Billroth I gastrectomy", Surg Laparosc Endosc, 4, pp.146~148 (1994)
42. Kim HH, "Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial)", Ann Surg, 251, pp.417~420 (2010)
43. Nakamura K, "A phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA", IB gastric Cancer (JCOG0912), 2013, pp.43, 324~327
44. Kim HH, "Long Longterm results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study", J Clin Oncol, 32, pp.627~633 (2014)
45. Choi YY, "Laparoscopic gastrectomy for advanced gastric cancer: are the long-term results comparable with conventional open gastrectomy? A systematic review and meta-analysis", J Surg Oncol, 108, pp.550~556 (2013)
46. Cai J, "A prospective randomized study comparing open versus laparoscopy-assisted D2 radical gastrectomy in advanced gastric cancer", Dig Surg, 28, pp.331~337 (2011)
47. Song J, "Robot-assisted gastrectomy with lymph node dissection for gastric cancer:lessons learned from an initial 100 consecutive procedures", Ann Surg, 249, pp.927~932 (2009)
48. Park SS, "Rapid adaptation of robotic gastrectomy for gastric cancer by experienced laparoscopic surgeons", Surg Endosc, 26, pp.60~67 (2012)
49. 손태일, "Minimally Invasive Surgery for Gastric Cancer Treatment: Current Status and Future Perspectives", Gut and Liver, 8(3), pp.229~236 (2014), 거트앤리버 발행위원회
50. Alessandra Marano, "Robotic versus Laparoscopic versus Open Gastrectomy: A Meta-Analysis", Journal of Gastric Cancer, 13(3), pp.136~148 (2013), 대한위암학회
51. Coratti A, "Robot-assisted gastrectomy for gastric cancer: current status and technical considerations", World J Surg, 37, pp.2771~2781 (2013)
52. Kunisaki C, "Significance of long-term follow-up of early gastric cancer", Ann Surg Oncol, 13, pp.363~369 (2006)
53. Isao Miyashiro, "What Is the Problem in Clinical Application of Sentinel Node Concept to Gastric Cancer Surgery?", Journal of Gastric Cancer, 12(1), pp.7~12 (2012), 대한위암학회
54. Kitagawa Y, "Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan", J Clin Oncol, 31, pp.3704~3710 (2013)
55. Keun Won Ryu, "The Future of Sentinel Node Oriented Tailored Approach in Patients with Early Gastric Cancer", Journal of Gastric Cancer, 12(1), pp.1~2 (2012), 대한위암학회
56. Ono H, "Endoscopic mucosal resection for treatment of early gastric cancer", Gut, 48, pp.225~229 (2001)
57. Gotoda T, "Incidence of lymph node metastasis from early gastric cancer:estimation with a large number of cases at two large centers", Gastric Cancer, 3, pp.219~225 (2000)
58. Lian J, "A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer", Gastrointest Endosc, 76, pp.763~770 (2012)
59. Choi JH, "Comparison of quality of life and worry of cancer recurrence between endoscopic and surgical treatment for early gastric cancer", Gastrointest Endosc (2015)
60. Macdonald JS, "Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction", N Engl J Med, 345, pp.725~730 (2001)
61. Cunningham D, "Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer", N Engl J Med, 355, pp.11~20 (2006)
62. Sakuramoto S, "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine", N Engl J Med, 357, pp.1810~1820 (2007)
63. Sasako M, "Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer", J Clin Oncol, 29, pp.4387~4393 (2011)
64. Bang YJ, "Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial", Lancet, 379, pp.315~321 (2012)
65. GASTRIC (Global Advanced, "Adjuvant Stomach Tumor Research International Collaboration) Group", Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis, 2010, pp.303, 1729~1737
66. Choi YY, "Advanced gastric cancer: is chemotherapy needed after surgery?", Expert Rev Gastroenterol Hepatol, 7, pp.673~675 (2013)
67. Lee J, "Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial", J Clin Oncol, 30, pp.268~273 (2012)
68. S. H. Park, "Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses", Journal of Clinical Oncology, 33(28), pp.3130~3136 (2015), American Society of Clinical Oncology (ASCO)[DOI]
69. Hurwitz H, "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer", N Engl J Med, 350, pp.2335~2342 (2004)
70. Sandler A, "Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer", N Engl J Med, 355, pp.2542~2550 (2006)
71. Kreisl TN, "Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma", J Clin Oncol, 27, pp.740~745 (2009)
72. Shah MA, "Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma", J Clin Oncol, 29, pp.868~874 (2011)
73. Ohtsu A, "Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study", J Clin Oncol, 29, pp.3968~3976 (2011)
74. Van Cutsem E, "Bevacizumab in combination with chemotherapy as firstline therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial", J Clin Oncol, 30, pp.2119~2127 (2012)
75. Fuchs CS, "Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial", Lancet, 383, pp.31~39 (2014)
76. Shah MA, "Gastrointestinal cancer: targeted therapies in gastric cancer-the dawn of a new era", Nat Rev Clin Oncol, 11, pp.10~11 (2014)
77. Committee on a Framework for Development a New Taxonomy of Disease, "Toward precision medicine: building a Knowledge network for biomedical research and a new taxonomy of disease" (2011), The national Academies press
78. Lauren P, "The two histological main types of gastric carcinoma:diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification", Acta Pathol Microbiol Scand, 64, pp.31~49 (1965)
79. "WHO Classification of Tumours of the Digestive System", International Agency for Research on Cancer, ~ (2010)
80. Ribic CM, "Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer", N Engl J Med, 349, pp.247~257 (2003)
81. Sargent DJ, "Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer", J Clin Oncol, 28, pp.3219~3226 (2010)
82. An JY, "Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection", Int J Cancer, 131, pp.505~511 (2012)
83. Choi YY, "Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis", J Surg Oncol, 110, pp.129~135 (2014)
84. Kim SY, "The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: results from a large cohort with subgroup analyses", Int J Cancer, 137, pp.819~825 (2015)
85. Cho JY, "Gene expression signature-based prognostic risk score in gastric cancer", Clin Cancer Res, 17, pp.1850~1857 (2011)
86. Wang K, "Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer", Nat Genet, 43, pp.1219~1223 (2011)
87. Boussioutas A, "Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer", Cancer Res, 63, pp.2569~2577 (2003)
88. Tan IB, "Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy", Gastroenterology, 141, pp.476~485 (2011)
89. Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma", Nature, 513, pp.202~209 (2014)
90. Cristescu R, "Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes", Nat Med, 21, pp.449~456 (2015)
91. Paving the Way for Personalized Medicine: FDA’s Role in a New Era of Medical Product Development, "US Food and Drug Administration", US Department of Health And Human Services, FDA, ~ (2013)
92. Gettinger SN, "Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer", J Clin Oncol, 33, pp.2004~2012 (2015)
93. Snyder A, "Genetic basis for clinical response to CTLA-4 blockade in melanoma", N Engl J Med, 371, pp.2189~2199 (2014)

관련 논문AI추천